SCHEMBL606872

SCHEMBL606872

COc1c(F)ccc(C(=O)O)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.49
MAPT P10636 1/20 0.49
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
MEP1B Q16820 1/20 0.43
ALDH1A1 P00352 3/20 0.41
HSD17B10 Q99714 2/20 0.41
HTT P42858 2/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 3/20 0.39
ASPH Q12797 1/20 0.39
KDM8 Q8N371 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 1/20 0.38
ALB P02768 1/20 0.37
TUBB1 Q9H4B7 2/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6215307 0.86 TDP1 (0.50) TDP1MAPTCES2CES1MEP1B
SCHEMBL116280 0.85 CES2 (0.45) TDP1MAPTCES2CES1MEP1B
SCHEMBL12756987 0.85 TDP1 (0.49) TDP1MAPTCES2CES1MEP1B
SCHEMBL1766176 0.83 MAPT (0.66) TDP1MAPTALDH1A1HTTLMNA
SCHEMBL201535 0.83 CES2 (0.44) TDP1MAPTCES2CES1MEP1B
SCHEMBL3808483 0.83 CES2 (0.48) MAPTCES2CES1MEP1BALDH1A1
SCHEMBL21262467 0.83 TDP1 (0.66) TDP1MAPTCES2CES1ALDH1A1
SCHEMBL24918 0.83 CES2 (0.44) TDP1MAPTCES2CES1MEP1B
SCHEMBL2925986 0.81 ALDH1A1 (0.58) TDP1MAPTMEP1BALDH1A1HSD17B10
SCHEMBL6693436 0.81 KDM4E (0.49) TDP1MAPTCES2CES1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079887-A Preparation method of nemonoxacin key intermediate 2026-05-26 CN claimed
CN-114106304-A Low-temperature curing weather-resistant polyester resin, low-temperature curing weather-resistant powder coating and preparation method 安徽神剑新材料股份有限公司 2022-03-01 CN claimed
CN-111530390-B Continuous production device and method of 2, 4-difluoro-3-methoxybenzoic acid 台州学院 2020-12-15 CN claimed
CN-111530390-A Continuous production device and method of 2, 4-difluoro-3-methoxybenzoic acid 台州学院 2020-08-14 CN claimed
CN-101298418-A Preparation method of 3-oxo-3- (2, 4-dihalogen-3-difluoromethoxyphenyl) ethyl propionate JIANGSU CHEMSPEC AGRO CHEMICAL (CN) 2008-11-05 CN claimed
CN-122079887-A Preparation method of nemonoxacin key intermediate 2026-05-26 CN disclosed
US-20250250269-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2025-08-07 US disclosed
CN-120423943-A Preparation method of 2, 4-difluoro-3-methoxybenzoic acid 苏州科伦药物研究有限公司 2025-08-05 CN disclosed
CN-120423943-A Preparation method of 2, 4-difluoro-3-methoxybenzoic acid 苏州科伦药物研究有限公司 2025-08-05 CN disclosed
CN-120136692-A Synthesis method of nemonoxacin malate intermediate 2, 4-difluoro-3-methoxy-1-benzoic acid 浙江昌海制药有限公司 2025-06-13 CN disclosed
CN-119528713-A Synthesis method of nemonoxacin intermediate 2, 4-difluoro-3-methoxy-1-benzoic acid 浙江昌海制药有限公司 2025-02-28 CN disclosed
EP-4508047-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2025-02-19 EP disclosed
EP-1015445-A1 ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES THE PROCTER & GAMBLE COMPANY (US) 2000-07-05 EP disclosed
WO-1999058521-A1 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed
WO-1999048851-A2 PROCESSES FOR PREPARING INTERMEDIATES AVENTIS CROPSCIENCE S.A. (FR) 1999-09-30 WO disclosed
WO-1999035117-A1 PROCESS FOR MAKING CERTAIN BENZOIC ACID COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 1999-07-15 WO disclosed
WO-1999014214-A1 ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES THE PROCTER & GAMBLE COMPANY (US) 1999-03-25 WO disclosed
US-5886016-A ANTIINFLAMMATORY AGENT WITH MINIMAL SIDE EFFECTS FOR TREATING ARTHRITIS G.D. SEARLE & CO. (US) 1999-03-23 US disclosed
WO-1998051153-A1 HERBICIDAL METHODS AND DERIVATIVES RHONE-POULENC AGRICULTURE LTD. (GB) 1998-11-19 WO disclosed
WO-1996009304-A1 BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250269-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, IAPP TDP1 2422/4885MAPT 3395/4885CES2 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.